August 17, 2017
Gilead Sciences’ hepatitis C therapy Harvoni (ledipasvir + sofosbuvir) was the best-selling drug in Japan for the second straight year in FY2016 despite its year-on-year sales slide of nearly 40%, with Ono Pharmaceutical’s Opdivo (nivolumab) ranking second with a 4.9-fold...read more